VH1-69-encoded immunoglobulin B-cell receptor (VH1-69 BCR)

The VH1-69-encoded immunoglobulin B-cell receptor (BCR) is a specific antigen receptor expressed on the surface of a significant subset of chronic lymphocytic leukemia (CLL) cells, characterized by the use of the IGHV1-69 germline gene. This receptor is a hallmark of unmutated CLL (U-CLL), a disease subtype associated with a more aggressive clinical course and poor response to traditional chemoimmunotherapy (Ghia et al., 2005, Blood). A unique feature of the VH1-69 BCR is its high degree of "stereotypy," where unrelated patients express nearly identical receptor sequences, particularly within "Subset 1," suggesting that the leukemia is driven by specific, recurring antigenic stimuli (Stamatopoulos et al., 2007, Blood). The signaling pathway initiated by this BCR is essential for the survival, proliferation, and tissue homing of the malignant B cells (Widhopf et al., 2004, Blood). While the receptor itself is not typically targeted by direct binders in clinical practice, its downstream signaling components, such as Bruton's tyrosine kinase (BTK), are the primary targets for highly effective therapies like ibrutinib and acalabrutinib (Burger & Wiestner, 2018, Nature Reviews Cancer). Consequently, identifying the presence of the VH1-69 BCR serves as a critical prognostic biomarker and guides the use of targeted kinase inhibitors.

Other names

IGHV1-69-encoded B-cell receptorVH1-69+ BCRStereotyped subset 1 B-cell receptorIGHV1-69 BCR

Inhibition of downstream B-cell receptor signaling via Bruton's tyrosine kinase (BTK) or PI3K inhibition